Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molnupiravir in Healthy Participants Inoculated With RSV
NCT05559905Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2022
- Primary completion
- Apr 2023
- Modality
- RNA-Targeting Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of molnupiravir in respiratory syncytial virus infection (RSV), sponsored by Merck & Co.. Started Nov 2022; status: completed.
02
Drugs
molnupiravir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05559905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05559905.